Krajska zdravotni a.s.

The team at Krajska zdravotni a.s. investigates therapies that strengthen immune defenses, aiming to reduce serious infections in patients with low antibody levels or receiving B‑cell depleting treatments.

• Prevention of major infections in hypogammaglobulinemia
• Safety and efficacy of B‑cell depletion therapy
• Evaluation of Panzyga (IVIG) for infection prophylaxis
• Novel immunomodulatory agents in autoimmune conditions

With 17 active trials and 22 investigators, the site in Teplice, Czechia contributes to advancing care for patients with compromised immune systems.

Researchers are developing regenerative approaches for joint damage, testing whether stem‑cell enriched scaffolds improve healing of knee cartilage lesions.

• Autologous MSC‑seeded 3D scaffolds combined with microfracture
• Bone‑marrow derived stem cell therapy for cartilage repair
• Comparison of scaffold‑only vs. cell‑enhanced techniques
• Clinical outcomes of chondral defect regeneration

The program leverages the hospital’s orthopedic expertise to explore innovative treatments that could restore joint function and reduce pain.

The centre conducts extensive studies on multiple sclerosis, evaluating new drugs that may slow disease activity, lessen relapses, and improve neurological function across its various forms.

• Relapsing‑remitting multiple sclerosis therapies
• Primary progressive multiple sclerosis interventions
• Secondary progressive multiple sclerosis trials
• Myelin oligodendrocyte glycoprotein antibody‑associated disease (MOG‑AD) research
• Spasticity management in MS patients

Across the neurological portfolio, 17 trials address disease progression, relapse reduction, and quality‑of‑life improvements for patients living with chronic neuro‑inflammatory conditions.

Although fewer studies target skin directly, the site supports investigations into connective‑tissue manifestations that often accompany systemic autoimmune disorders.

• Connective tissue involvement in autoimmune disease trials
• Monitoring skin‑related adverse events during immunotherapy
• Biomarker evaluation for connective tissue disease activity

This research helps clinicians better understand and manage the dermatologic and connective‑tissue aspects of complex immune‑mediated illnesses.